New light commercial vehicle (LCV) registrations fell by 12.1% to 156,048 units in the first half of 2025, according to the ...

Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

New diesel van registrations shrank by 12.1% to 156,048 units in the first half of 2025, whilst electric van demand rose by ...

Fintel reports that on July 1, 2025, UBS initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Buy recommendation.

The new car market recorded its second consecutive month of growth in June, with registrations rising 6.7% year-on-year ...

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Sales remained below pre-COVID levels, but it was the best June since 2019, the Society of Motor Manufacturers and Traders ...

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts.

Tesla's new car sales in Britain rose year-on-year in June amid a broader recovery in the electric-vehicle market, data showed on Friday, as the U.S. auto maker started deliveries of its updated Model ...